Início › Carcinoma urotelial (células de transição) › Illinois › Chicago
Ensaios clínicos de Carcinoma urotelial (células de transição) em Chicago, IL
14 estudos para Carcinoma urotelial (células de transição) estão buscando participantes em locais em Chicago e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RecrutandoFase 1
- Exelixis Clinical Site #26, Chicago
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
RecrutandoFase 3
- University of Illinois, Chicago
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RecrutandoFase 2
- Rush MD Anderson Cancer Center, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
RecrutandoEstudo observacional
- Northwestern University, Chicago
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
RecrutandoFase 1/2
- University of Chicago Medical Center ( Site 1037), Chicago
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
RecrutandoFase 3
- University of Illinois at Chicago, Chicago
- University of Chicago Medical Center, Chicago
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RecrutandoFase 1
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
RecrutandoFase 2
- UChicago Medicine - River East, Chicago
- University of Chicago Medical Center, Chicago
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RecrutandoFase 1/2
- The University of Chicago Medical Center - Oncology, Chicago
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
RecrutandoFase 2
- Site 02-012 - University of Chicago, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecrutandoEstudo observacional
- Massive Bio SYNERGY-AI site, Chicago
Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer
RecrutandoEstudo observacional
- Jesse Brown Department Of Veterans Affairs Medical Center, Chicago
A Study of NX-1607 in Adults With Advanced Malignancies
RecrutandoFase 1
- University of Chicago, Chicago
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
RecrutandoFase 2
- Northwestern University, Chicago
Ensaios de Carcinoma urotelial (células de transição) em outras cidades
- Nashville, TN23 estudos
- New York City, NY22 estudos
- Dallas, TX18 estudos
- Edison, NJ18 estudos
- Houston, TX18 estudos
- Los Angeles, CA17 estudos
- Queens, NY15 estudos
- Arlington, VA12 estudos
- San Antonio, TX11 estudos
- Boston, MA11 estudos
- Austin, TX10 estudos
- Orange, CA10 estudos
Outros estudos em Chicago
- Câncer de Pulmão de Não Pequenas Células61 estudos
- Câncer de Mama58 estudos
- Câncer (todos os tipos)51 estudos
- Câncer Metastático45 estudos
- Câncer de Próstata45 estudos
- Obesidade41 estudos
- Câncer de Pulmão41 estudos
- Câncer de Ovário36 estudos
- Acidente Vascular Cerebral34 estudos
- Câncer Colorretal33 estudos
- Insuficiência Cardíaca31 estudos
- Sobrepeso28 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.